Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience
Anadolu Kliniği Tıp Bilimleri Dergisi · 23.05.2026 · 31 (2) · 302-309
DOI: 10.21673/anadoluklin.1840385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anadolu Kliniği Tıp Bilimleri Dergisi, online erschienen am 23.05.2026. Verfasst von Emre Urhan. Die Arbeit nennt 19 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To evaluate the early glycemic, weight, and metabolic effects of the fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) in patients with uncontrolled type 2 diabetes mellitus (T2DM) despite treatment with oral antidiabetic agents (OADs) and/or single or multiple insulin regimens, and to generate real-world evidence regarding its clinical effectiveness.
Methods
This retrospective single-center study included adults with T2DM who initiated iGlarLixi at Burdur State Hospital between June 2024 and January 2025 and used it for at least three months. Patients aged ≥ 18 years with body mass index (BMI) > 35 kg/m² and hemoglobin A1c (HbA1c) ≥ 7% were included. iGlarLixi was administered once daily (100/33 or 100/50) with dose titration to fasting glucose targets. Baseline and 3-month measurements of weight, BMI, HbA1c, fasting glucose, lipid profile, and routine laboratory parameters were compared.
Results
Among the 65 individuals enrolled, 62 were able to complete the 3-month course of iGlarLixi therapy. During follow-up, we noted reductions in body weight, BMI, HbA1c, fasting plasma glucose, and triglycerides, whereas high-density lipoprotein cholesterol showed a significant rise. Overall, 71% of patients showed a reduction in HbA1c and 29% achieved HbA1c
Zitieren
APA
Urhan, E. (2026). Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience. Anadolu Kliniği Tıp Bilimleri Dergisi, 31(2), 302-309. https://doi.org/10.21673/anadoluklin.1840385
Vancouver
Urhan E. Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience. Anadolu Kliniği Tıp Bilimleri Dergisi. 2026;31(2):302-309. doi:10.21673/anadoluklin.1840385
BibTeX
@article{Urhan2026,
author = {Urhan, Emre},
title = {Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience},
journal = {Anadolu Kliniği Tıp Bilimleri Dergisi},
year = {2026},
volume = {31},
number = {2},
pages = {302--309},
doi = {10.21673/anadoluklin.1840385}
}
EUVIMED